News • Thu, Sep. 4
News • Aug. 16, 2013
There are no Focus articles on JBSAY.
There are no Transcripts on JBSAY.
Thu, Sep. 4, 1:10 PM
- JBS S.A. (OTCQX:JBSAY) is close to finalizing a date for the IPO of its JBS Foods business in Brazil, according to Reuters.
- The offering is expected to raise as much as $1.8B after being delayed from a June launch.
- The company will time the public debut of JBS Foods carefully around the presidential election voting rounds in October during which some extra volatility in the market is anticipated.
Thu, Jun. 12, 2:17 PM
- After missing out on Hillshire Brands and Smithfield Foods, Brazilian food giant JBS S.A. (JBSAY) has a narrower list of acquisition targets, according to Deutsche Bank.
- Oscar Meyer (KRFT) and Hormel Foods (HRL) are two big-target options for JBS, while Maple Leaf Foods MFI and Sanderson Farms SAFM are on the lighter side.
Dec. 30, 2013, 9:14 AM| Comment!
Sep. 13, 2013, 12:59 PM
- "The performance of the world's two largest beef-processing industries will differ markedly through next year," Moody's says, referencing challenging conditions for the U.S. market and a strong cycle in Brazil.
- Earnings for U.S. companies will "be the worst in a decade" in 2013 and 2014, Moody's thinks.
- Brazilian producers, by contrast, "should remain profitable" even as "their EBITA margins could deteriorate next year due partly to higher costs related to recent capacity expansion and to expectations of no further decreases in cattle prices."
- Diversified players such as Tyson (TSN) and JBS S.A. (JBSAY.PK -2.6%) should be able to offset beef business profit declines with "stronger earnings from other proteins."
- Pure beef players like Minerva (MRVSY.PK) may face pressure "when the cycle turns" in Brazil.
Aug. 16, 2013, 2:43 PM
- Merck (MRK -0.8%) defends Zilmax in light of its earlier decision to pull it off the market, saying it hasn't seen any safety or effectiveness issues beyond those observed in clinical trials before it was introduced in the United States in 2007.
- "You will see lameness even in normal feedlots in animals that are not given beta agonists," says K.J. Varma, head of research for MRK's animal health unit. "Based on studies we've done, we don't see anything out of the ordinary in terms of lameness" associated with Zilmax.
- The company has done 30 studies in 60,000 animals since Zilmax was introduced,
- Separately, Brazil's JBS SA (JBSAY.PK) says it will continue to accept animals fed with Zilmax at its U.S. operations unless evidence emerges that the product is potentially harmful to their well-being, CEO Wesley Batista said in an interview.
JBSAY vs. ETF Alternatives
JBS is a global leader in beef, lamb and poultry processing and is also heavily involved in pork production. With over 185,000 employees worldwide, the company has 340 production units and businesses in the foodstuffs, leather, biodiesel, collagen, metal packaging and cleaning products... More
Other News & PR